| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC3072 |
| Trial ID | NCT05418088 |
| Disease | Chronic Lymphocytic Leukemia | Acute Lymphoblastic Leukemia | B-Cell Lymphoma | B-Cell Prolymphocytic Leukemia | B-Cell Acute Lymphoblastic Leukemia | Non-Hodgkin's Lymphoma |
| Altered gene | CD19|CD20|CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19/CD20/CD22 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies |
| Year | 2022 |
| Country | United States |
| Company sponsor | Sumithira Vasu |
| Other ID(s) | OSU-21170|NCI-2022-02972 |
| Cohort 1 | |||||||||||
|
|||||||||||